Picture of Arecor Therapeutics logo

AREC Arecor Therapeutics News Story

gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock


For best results when printing this announcement, please click on link below:

RNS Number : 0350I  Arecor Therapeutics PLC  12 April 2022

Arecor Therapeutics plc

("Arecor" or the "Group")





Cambridge, UK, 12 April 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that its abstract titled "AT278 (U500) - PK/PD and safety of rapid-acting concentrated insulin aspart", has been selected for oral presentation at the upcoming 15(th) International Conference on Advanced Technologies and Treatments For Diabetes
(ATTD (https://attd.kenes.com/scientific-program/)
) meeting which will be held from 27-30 April 2022 in Barcelona.


The presentation will take place at 17:20 on Thursday 28 April during the Oral Presentations Session 2 in Hall 118 of the Conference Centre.


Oral Presentation:          AT278 (U500) - PK/PD and safety of
rapid-acting concentrated insulin aspart

Presenting Author:         Dr Eva Svehlikova

Session:                             Oral Presentations Session

Date and Time:                Thursday, 28 April 2022, at 17:20
Central European Time


AT278 is an ultra-concentrated (500U/mL) novel formulation of insulin that has
been designed to significantly accelerate insulin absorption post injection to
enable more effective and convenient management of blood glucose levels in
people with high daily insulin requirements.


In addition, a poster titled 'Adjusting insulin therapy to faster insulin
analogs leads to improved glucose control: An in-silico analysis' will be
presented at ATTD by Dr Jenny Diaz from the University of Virginia.  The
in-silico analysis suggests that the faster PK/PD profile of Arecor's AT247,
an investigational ultra-rapid acting (100U/mL) insulin formulation, has the
potential to significantly improve glucose control in closed loop systems.


Sarah Howell, Chief Executive Officer at Arecor, said: "We are very excited to
be able to share these ground-breaking data for AT278 and AT247 at the ATTD
conference. AT278 has the potential to be the first and perhaps only
concentrated (500U/mL) rapid acting insulin available to patients, having
clearly demonstrated faster insulin absorption with an accelerated
pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to
gold-standard insulin NovoRapid® despite a 5-fold increase in concentration,
in this first Phase I clinical study. In addition, in partnership with the
University of Virginia, we are excited to be able to share results from their
in-silico analysis demonstrating the potential for AT247 to enable a fully
closed loop artificial pancreas, which would be a life-changing treatment
option for people living with Type 1 diabetes."


About the ATTD

The International Conference on Advanced Technologies and Treatments of
Diabetes (ATTD) was established in 2008 and has held annual meetings since
then. The purpose of the ATTD meeting is to highlight innovative
technologies in diabetes treatment. It brings together developers of new
technologies with the diabetes professionals and caretakers as well as
acquainting clinicians with techniques for new treatments.




For more information, please contact:


 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray         Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com


Notes to Editors


About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.


For further details please see our website, www.arecor.com


About AT278

AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin designed to
accelerate the absorption of insulin post injection, to enable more effective
management of blood glucose levels to the increasing number of people with
diabetes with high daily insulin requirements (>200 units/day), whilst
maintaining the convenience and compliance benefits of being able to deliver
these high insulin doses in a lower injection volume via a single injection.
A truly rapid acting concentrated insulin is a critical step towards the
advancement and miniaturisation of the next generation of insulin delivery


About AT247

AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption,
post injection, to enable more effective management of blood glucose levels
for people living with diabetes, particularly around difficult to manage
mealtimes.  Early clinical evidence suggests that AT247 may facilitate a
fully closed loop artificial pancreas, a potentially life changing treatment
option for people living with diabetes, and a US Phase I clinical trial is
currently underway investigating the potential of the product when delivered
by continuous subcutaneous infusion via insulin pump.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)

Recent news on Arecor Therapeutics

See all news